A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along ...

The 23andMe Research Institute bought the company's assets for $305 million, scotching a proposed sale to Regeneron ...

Since an investor revolt early this year at Air Products and Chemicals, the new leadership at the industrial gas giant has ...

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the yearTessera to receive $150 ...

In a bid to deepen its manufacturing foothold in the U.S., Regeneron Pharmaceuticals in April pledged production and infrastructure investments surpassing $7 billion across North Carolina and its ...

The former Quad Graphics property is seen on Thursday in Saratoga Springs. Drug development and manufacturing firm Regeneron is building a 1-million-square-foot facility on the site. (Will ...

Tarrytown-based Regeneron bought the former Avon complex at 1 Avon Place in Suffern in early 2024 for $38.875 million. The biotech company planned another $100 million in renovations at the site, ...

Regeneron is buying in to Modex Therapeutics’ next-generation antibody platform with a $7 million upfront payment and a total potential deal value exceeding $1 billion. The New York-based biopharma ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Tuesday reported third-quarter adjusted earnings of $11.83 per share, down 5% year-over-year, beating the consensus of $9.59. The company reported sales ...

Regeneron has settled its patent dispute with Celltrion, giving the go-ahead for another biosimilar to its blockbuster eye drug Eylea (aflibercept) to hit the U.S. market in just over a year. The deal ...

On her mother’s instruction, a toddler gives her pink stuffed horse, Snap Snap, a big cuddle. Then, as told, she plants a kiss on his soft fur and, because he’s hungry, feeds him a pretend bowl of ...